Cantor Fitzgerald initiated coverage of Phathom Pharmaceuticals (PHAT) with an Overweight rating and $23 price target
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.